MedTrace Logo

Liver Transplantation Results in Hepatocellular Carcinoma Patients With Immunosuppression Without Steroids

NCT01137084 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2010-06-04

No results posted yet for this study

Summary

The purpose of this study was to evaluate the safety and efficacy of a steroid-free immunosuppression protocol in Hepatocellular Carcinoma (HCC) patients.

Conditions

Interventions

DRUG

solu medrol

total dose 20mg/kg, including first dose 10mg/kg, rest of drug given within one weeks after liver transplantation

DRUG

a steroid-free immunosuppression protocol

receive immunosuppression with Basiliximab(20mg/day,twice following transplantation) and tacrolimus(0.06/kg/d,twice a day) without steroids.

Sponsors & Collaborators

  • First Affiliated Hospital of Fujian Medical University

    collaborator OTHER

  • Nanchang University

    collaborator OTHER

  • Zhejiang University

    collaborator OTHER

  • Shanghai Changzheng Hospital

    collaborator OTHER

  • Shanghai Jiao Tong University School of Medicine

    lead OTHER

Principal Investigators

  • Zhi-Hai Peng, MD · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31
Primary Completion
2008-01-31
Completion
2009-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01137084 on ClinicalTrials.gov